PortalPublikationenIbrutinib as a salvage therapy after allogeneic HCT for chro...

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Standard

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. / Michallet, Mauricette; Dreger, Peter; Sobh, Mohamad; Koster, Linda; Hoek, Jennifer; Boumendil, Ariane; Scheid, Christof; Fox, Christopher P; Wulf, Gerald; Krüger, William; van Gelder, Michel; Corradini, Paolo; Russo, Domenico; Passweg, Jakob; Schoemans, Hélène; Bethge, Wolfgang; Schaap, Nicolaas; Cornelissen, Jan; Browne, Paul; Durakovic, Nadira; Muller, Lutz; Montoto, Silvia; Kroger, Nicolaus; Schetelig, Johannes; French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties.

in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 5, 05.2020, S. 884-890.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Michallet, M, Dreger, P, Sobh, M, Koster, L, Hoek, J, Boumendil, A, Scheid, C, Fox, CP, Wulf, G, Krüger, W, van Gelder, M, Corradini, P, Russo, D, Passweg, J, Schoemans, H, Bethge, W, Schaap, N, Cornelissen, J, Browne, P, Durakovic, N, Muller, L, Montoto, S, Kroger, N, Schetelig, J & French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties 2020, 'Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia', BONE MARROW TRANSPL, Jg. 55, Nr. 5, S. 884-890. https://doi.org/10.1038/s41409-019-0742-7

APA

Michallet, M., Dreger, P., Sobh, M., Koster, L., Hoek, J., Boumendil, A., Scheid, C., Fox, C. P., Wulf, G., Krüger, W., van Gelder, M., Corradini, P., Russo, D., Passweg, J., Schoemans, H., Bethge, W., Schaap, N., Cornelissen, J., Browne, P., ... French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties (2020). Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. BONE MARROW TRANSPL, 55(5), 884-890. https://doi.org/10.1038/s41409-019-0742-7

Vancouver

Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A et al. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. BONE MARROW TRANSPL. 2020 Mai;55(5):884-890. https://doi.org/10.1038/s41409-019-0742-7

Bibtex

@article{0b2e8fe841474d19a5d717b28ddafb7b,
title = "Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia",
abstract = "The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.",
author = "Mauricette Michallet and Peter Dreger and Mohamad Sobh and Linda Koster and Jennifer Hoek and Ariane Boumendil and Christof Scheid and Fox, {Christopher P} and Gerald Wulf and William Kr{\"u}ger and {van Gelder}, Michel and Paolo Corradini and Domenico Russo and Jakob Passweg and H{\'e}l{\`e}ne Schoemans and Wolfgang Bethge and Nicolaas Schaap and Jan Cornelissen and Paul Browne and Nadira Durakovic and Lutz Muller and Silvia Montoto and Nicolaus Kroger and Johannes Schetelig and {French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties}",
year = "2020",
month = may,
doi = "10.1038/s41409-019-0742-7",
language = "English",
volume = "55",
pages = "884--890",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

AU - Michallet, Mauricette

AU - Dreger, Peter

AU - Sobh, Mohamad

AU - Koster, Linda

AU - Hoek, Jennifer

AU - Boumendil, Ariane

AU - Scheid, Christof

AU - Fox, Christopher P

AU - Wulf, Gerald

AU - Krüger, William

AU - van Gelder, Michel

AU - Corradini, Paolo

AU - Russo, Domenico

AU - Passweg, Jakob

AU - Schoemans, Hélène

AU - Bethge, Wolfgang

AU - Schaap, Nicolaas

AU - Cornelissen, Jan

AU - Browne, Paul

AU - Durakovic, Nadira

AU - Muller, Lutz

AU - Montoto, Silvia

AU - Kroger, Nicolaus

AU - Schetelig, Johannes

AU - French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties

PY - 2020/5

Y1 - 2020/5

N2 - The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

AB - The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

U2 - 10.1038/s41409-019-0742-7

DO - 10.1038/s41409-019-0742-7

M3 - SCORING: Journal article

C2 - 31700137

VL - 55

SP - 884

EP - 890

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -